hVIVO PLC (AIM:HVO) posted record results for 2024, with revenue up 12% and a bumper 26% EBITDA margin. CEO Mo Khan says hVIVO is targeting £73 million in revenue for 2025, of which 70% is already contracted.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) is branching into eye care, developing a gene therapy using its SIRT6 longevity tech. The treatment targets glaucoma and corneal conditions and uses a non-viral delivery system.
Ananda Pharma Plc (AQSE:ANA) has brought in ex-GW Pharma exec Chris Tovey as a strategic adviser. It’s also cleared ethics approval for its first human trial of MRX1, with recruitment starting soon in Australia.
SSV Capital PLChas paid off a £2.5 million loan early, citing strong investor confidence. It’s scaling up its fintech and proptech platforms and pushing into private equity in 2025.
Directa Plus PLC (AIM:DCTA, OTC:DTPKF) grew Q1 revenue by 40%, driven by new contracts and its full takeover of Setcar. It’s also making moves in graphene-based environmental clean-up, battery tech and even PFAS filtration.